Royal Bank of Canada
BPMC

Royal Bank of Canada’s Blueprint Medicines BPMC Stock Holding History

Royal Bank of Canada’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,712
Closed -$861K – 7141
2025
Q2 		$861K Sell
6,712
-20,102
-75% -$2.09M ﹤0.01% 4029
2025
Q1 		$2.37M Buy
26,814
+17,882
+200% +$1.74M ﹤0.01% 2825
2024
Q4 		$779K Sell
8,932
-8,072
-47% -$739K ﹤0.01% 3734
2024
Q3 		$1.57M Buy
17,004
+8,121
+91% +$807K ﹤0.01% 3158
2024
Q2 		$957K Buy
8,883
+4,396
+98% +$440K ﹤0.01% 3491
2024
Q1 		$425K Sell
4,487
-17,042
-79% -$1.46M ﹤0.01% 4090
2023
Q4 		$1.99M Buy
21,529
+10,456
+94% +$677K ﹤0.01% 3083
2023
Q3 		$555K Buy
11,073
+4,174
+61% +$223K ﹤0.01% 3956
2023
Q2 		$436K Buy
6,899
+441
+7% +$24K ﹤0.01% 4055
2023
Q1 		$290K Sell
6,458
-5,783
-47% -$261K ﹤0.01% 4323
2022
Q4 		$535K Buy
12,241
+8,499
+227% +$408K ﹤0.01% 4056
2022
Q3 		$246K Sell
3,742
-990
-21% -$63.6K ﹤0.01% 4592
2022
Q2 		$239K Sell
4,732
-2,847
-38% -$167K ﹤0.01% 4659
2022
Q1 		$484K Sell
7,579
-10,293
-58% -$739K ﹤0.01% 4304
2021
Q4 		$1.91M Buy
17,872
+8,792
+97% +$920K ﹤0.01% 3192
2021
Q3 		$934K Sell
9,080
-17,031
-65% -$1.59M ﹤0.01% 3771
2021
Q2 		$2.3M Sell
26,111
-25,977
-50% -$2.38M ﹤0.01% 2942
2021
Q1 		$5.07M Sell
52,088
-4,110
-7% -$410K ﹤0.01% 2225
2020
Q4 		$6.3M Buy
56,198
+518
+0.9% +$54.6K ﹤0.01% 2027
2020
Q3 		$5.16M Sell
55,680
-15,010
-21% -$1.16M ﹤0.01% 1982
2020
Q2 		$5.51M Buy
70,690
+1,943
+3% +$131K ﹤0.01% 1875
2020
Q1 		$4.02M Buy
68,747
+60,959
+783% +$3.92M ﹤0.01% 1965
2019
Q4 		$623K Buy
7,788
+4,593
+144% +$344K ﹤0.01% 3807
2019
Q3 		$235K Sell
3,195
-16,730
-84% -$1.45M ﹤0.01% 4355
2019
Q2 		$1.88M Sell
19,925
-8,481
-30% -$700K ﹤0.01% 2822
2019
Q1 		$2.27M Sell
28,406
-81,515
-74% -$6.02M ﹤0.01% 2582
2018
Q4 		$5.92M Buy
109,921
+5,574
+5% +$339K ﹤0.01% 1857
2018
Q3 		$8.14M Buy
104,347
+29,048
+39% +$2.02M ﹤0.01% 1748
2018
Q2 		$4.78M Buy
75,299
+75,246
+141,974% +$5.99M ﹤0.01% 2039
2018
Q1 		$5K Sell
53
-259
-83% -$22.3K ﹤0.01% 5918
2017
Q4 		$23K Sell
312
-118,713
-100% -$8.35M ﹤0.01% 5543
2017
Q3 		$8.29M Buy
119,025
+118,902
+96,668% +$6.35M ﹤0.01% 1665
2017
Q2 		$6K Sell
123
-520
-81% -$22.1K ﹤0.01% 5971
2017
Q1 		$26K Sell
643
-184
-22% -$6.59K ﹤0.01% 5483
2016
Q4 		$23K Buy
+827
New +$24.9K ﹤0.01% 5693
2016
Q1 		– Sell
-13
Closed – – 6353
2015
Q4 		$0 Sell
13
-406
-97% -$9.14K ﹤0.01% 6633
2015
Q3 		$9K Sell
419
-155
-27% -$4.29K ﹤0.01% 5928
2015
Q2 		$15K Buy
+574
New +$16.4K ﹤0.01% 5849

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Royal Bank of Canada's BPMC Position: Q3 2025 in Review

Royal Bank of Canada sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 6,712 shares — an estimated $861K sold.

Royal Bank of Canada first reported a position in BPMC in Q2 2015 and held it in 38 quarters. The position peaked at $8.29M in Q3 2017. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Royal Bank of Canada reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 6,712 Blueprint Medicines shares in Q3 2025, an estimated $861K.
  • Royal Bank of Canada first reported a position in Blueprint Medicines in Q2 2015 and held it in 38 quarters.
  • Royal Bank of Canada's Blueprint Medicines position peaked at $8.29M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Royal Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.